Loading...
Please wait, while we are loading the content...
Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis
| Content Provider | Scilit |
|---|---|
| Author | Volarevic, Vladislav Al-Qahtani, Ahmed Arsenijevic, Nebojsa Pajovic, Sladjana Lukic, Miodrag L. |
| Copyright Year | 2009 |
| Description | The increase of pro-inflammatory cytokines and oxidative stress leads to beta-cell damage and promotes beta-cells apoptosis, in types I and II of diabetes mellitus. Therefore, blocking of pro-inflammatory cytokines should be an effective way for the treatment of diabetes mellitus. When IL-1 occupies its receptor, various pro-inflammatory events are initiated including the synthesis and releases of chemokines and these chemokines attract neutrophils, macrophages, and lymphocytes that cause tissue inflammation. IL-1Ra is a naturally occurring cytokine and is the inhibitor of IL-1. When IL-1Ra binds to the IL-1 receptor, binding of IL-1 is blocked by IL-1Ra and pro-inflammatory signal from IL-1 receptor is stopped. There are mounting evidences to suggest that anti-inflammatory IL-1Ra reduces the inflammatory effects of IL-1 and preserves cell function in both types of diabetes. Therefore, IL-1Ra maybe a new therapeutic agent for diabetes mellitus types I and II. Mesenchymal stem cells (MSCs) are self-renewable multipotent stromal cells that have immunomodulatory capacity. Recently, well characterized subpopulations of MSCs which express IL-1Ra have been described. IL-1Ra expressed by these MSCs effectively binds to IL-1 receptor and protects tissues from inflammation-induced injuries. It has been previously shown that bone marrow-derived MSC therapy could be considered for the treatment of diabetes mellitus type 1 and complications of diabetes mellitus. This review presents understanding of potential use of IL-1Ra and MSCs as modulators of diabetogenesis. |
| Related Links | http://www.tandfonline.com/doi/pdf/10.3109/08916930903305641 |
| Ending Page | 263 |
| Page Count | 9 |
| Starting Page | 255 |
| ISSN | 08916934 |
| e-ISSN | 1607842X |
| DOI | 10.3109/08916930903305641 |
| Journal | Autoimmunity |
| Issue Number | 4 |
| Volume Number | 43 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2009-10-22 |
| Access Restriction | Open |
| Subject Keyword | Journal: Autoimmunity Toxicology Interleukin-1 Receptor Antagonist Mesenchymal Stem Cells Diabetes Mellitus Prevention Therapy |
| Content Type | Text |
| Resource Type | Article |
| Subject | Immunology and Allergy Immunology |
